Method for preparing compound controlled release capsule for treating benign prostatic hyperplasia and the compound controlled release capsule

Abstract

The invention discloses a method for preparing a compound controlled-release capsule for treating benign hyperplasia of prostate and the compound controlled-release capsule for treating the benign hyperplasia of prostate, and belongs to the technical field of medicines. The method comprises that: common micro pills containing the finasteride medicine and slow release micro pills containing the doxazosin pills are prepared respectively, and the two kinds of micro pills are mixed and encapsulated to prepare the controlled-release capsule, wherein the mass ratio of the finasteride medicine to the doxazosin medicine in the capsule is 1:0.625-2.5. In the method, ethylcellulose and hydroxypropyl emthylcellulose are used as auxiliary materials of the slow release preparation, and by combining the preparation process by which the auxiliary materials is mutually cooperated with compound medicines, the finasteride-doxazosin compound controlled-release capsule is prepared. Active ingredients in the two medicines in the preparation not only can be mutually cooperated to achieve better curative effects, but also can stably release the medicines, avoid the difference between blood concentration at wave crest and wave hollow, and reduce toxic and side effects of the medicines on human body; moreover, the controlled-release capsule can also shorten the medicine taking time of patients and improve compliance of taking medicines. The finasteride-doxazosin controlled-release capsule can be used as the medicine to treat hypertension and benign hyperplasia of prostate.

Description

Technical field: [0001] The invention belongs to the technical field of medicine, relates to a drug preparation for treating high blood pressure and benign prostatic hyperplasia, in particular to a preparation method of a preparation with controlled-release ability prepared by compounding two or more drugs. Background technique: [0002] Benign prostatic hyperplasia is a common senile disease in men. The main reason is the increase in age and the existence of functional testicles. The urinary obstruction caused by two main reasons: one is the testosterone produced by the testis, and the function of α1 reductase Under the action, it is transformed into dihydrotestosterone, which acts on the prostate to make the prostate hyperplasia. The protruding gland protrudes into the bladder, compressing the urethra and causing mechanical obstruction of the bladder outlet. On the other hand, the bladder neck, posterior urethra, prostatic body, and capsule are rich in α-receptors. Due to...

AI Technical Summary

Problems solved by technology

The disadvantage of this method is that the precision of the controlled release of the process is still lacking, and the drug pellets made by this process cannot effectively control and coordinate the release speed and degree of the drug.

In addition, the goal of this patent is to prepare single-drug capsules. In the selection and design of excipients, only the matching with the single drug should be considered. The selection of auxiliary materials and the preparation procedure of sustained-release pellets are not suitable for compound controlled-release drugs.

Images